Edison Investment Research - Polski Bank Komorek Macierzystych (BKM) Polski Bank Komórek Macierzystych - European leader in stem cell banking

Report

Edison Investment Research

Sean Conroy

Polski Bank Komórek Macierzystych - European leader in stem cell banking

Polski Bank Komórek Macierzystych (PBKM) continues its consolidation efforts in the cord blood banking services market in Europe. It operates 15 stem cell banks under the FamiCord brand, covering approximately 37% of the European market for newly acquired samples, seeing space for further growth in Western Europe. PBKM is present in 11 European countries, with partners in a further 13 regions. Recent steady growth (2015–19 revenue CAGR of 16%) has been fuelled by both organic development and M&A.

21/10/2020 2 EN

Underlying

Polski Bank Komorek Macierzystych

Polski Bank Komorek Macierzystych SA (PBKM) is a Poland-based company that carries out full set of researches from umbilical cord blood. PBKM is the cord blood bank in Poland, which is one of public and private cord banks in Europe accredited by American Association of Blood Banks (AABB). The Company cooperates with the Institute of Human Genetics PAS (Polish Academy of Sciences), Medicover, LUX MED Salus Clinic, Medical Centers Salve, as well as Falck Sp z o o and Alab Laboratories, among others. The public cord blood bank aims to increase the resources of the stored cord blood and the use of cord blood for transplantation in Poland. The Company forms a part of the international group of banks of stem cells from umbilical cord blood, FamiCord, which consists of laboratories in Poland, Hungary, Romania, Spain and Turkey, and which collaborates with over 1100 hospitals throughout Europe.

See profile

PLPBKM000012 Warsaw Stock Exchange Poland

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

Polski Bank Komórek Macierzystych - European leader in stem-cell banking

Polski Bank Komórek Macierzystych (PBKM) continues its consolidation efforts in the cord-blood banking in Europe. It holds a c 40% share of the European stem-cell banking market in terms of processed cord blood samples. The market is expected to grow at a double-digit rate globally (Grand View Research) through increased penetration of the service. PBKM has been also involved in 10 clinical trials in stem-cell research, acts as a contract manufacturing organisation and runs a one-day clinic.

November 8, 2021 November 8, 2021 1 EN

Edison Investment Research

Polski Bank Komórek Macierzystych - European leader in stem-cell banking

November 8, 2021 November 8, 2021 1 EN

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

May 17, 2024 May 17, 2024 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

May 17, 2024 May 17, 2024 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

May 17, 2024 May 17, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Polski Bank Komórek Macierzystych - European leader in stem cell banking

Polski Bank Komórek Macierzystych - European leader in stem-cell banking

Polski Bank Komórek Macierzystych - European leader in stem-cell banking

Monthly LMI Update Independent Investment Research

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

AAC Clyde Space - Solid start to the year with further order growth

Tinexta - Typical seasonality in Q124

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe